LECOM Health Challenge

LECOM Opens New School of Podiatric Medicine

Retrieved on: 
Monday, November 28, 2022
DPM, Head, Dentistry, Conditional sentence, American College, University of Puerto Rico School of Dental Medicine, Payment, Lake Erie College of Osteopathic Medicine, Student, Hospital, American College of Foot and Ankle Surgeons, Physician, College, LECOM, Patient, Joint, LECOM Health Challenge, Pharmacy school, Ageing, Graduate school, Biomedical sciences, Council, Diabetes, American Board of Commissioners for Foreign Missions, California School of Podiatric Medicine, School, Des Moines University, Graduate School of Biomedical Sciences, Moyamoya disease, Substance Abuse and Mental Health Services Administration, Osteopathic medicine in the United States, Mill Creek, Health care, Lake Erie College, Obesity, Medicine, Veterinary medicine, Podiatry, Foot

ERIE, Pa., Nov. 28, 2022 /PRNewswire/ -- The Lake Erie College of Osteopathic Medicine (LECOM) announced it will open a new School of Podiatric Medicine (SPM). The LECOM-SPM Erie (PA) received approval from the accreditation agency, the Council on Podiatric Medical Education, to begin accepting students for the fall semester of 2023. The LECOM-SPM is the eleventh podiatric medical school in the United States. The four-year program will be located at LECOM's main campus in Erie, Pennsylvania and will offer a unique curricular collaboration with LECOM's College of Osteopathic Medicine.

Key Points: 
  • New school is the 11th podiatric medical school in the U.S. First class will begin in 2023
    ERIE, Pa., Nov. 28, 2022 /PRNewswire/ -- The Lake Erie College of Osteopathic Medicine (LECOM) announced it will open a new School of Podiatric Medicine (SPM).
  • The LECOM School of Podiatric Medicine is the eleventh podiatric medical school in the United States.
  • Dr. Lee earned his degree in podiatric medicine from Des Moines University College of Podiatric Medicine and Surgery.
  • Enrollment in the College of Osteopathic Medicine, School of Pharmacy, School of Dental Medicine, School of Podiatric Medicine, School of Health Services Administration and Graduate School of Biomedical Sciences has surpassed 4,400 students at campuses in Erie and Greensburg, Pa., Bradenton, Fla., and Elmira,
    N.Y. LECOM consistently graduates more primary care physicians than any other U.S. medical college while maintaining one of the lowest tuitions of any private medical school in the country.

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

Retrieved on: 
Tuesday, October 4, 2022
Algorithm, Concussion, Senior advisor, MT3, OPKO Health, Family, Prognosis, Diagnosis, BDNF, Posture, Psychology, Book, Sports medicine, Medtech, Brainbox, NIH, Patent, Athlete, GFAP, MRI, Developing Solutions, Inc, TBI, Neuroimaging, Health, László, J&J, Cuban medical internationalism, PTO, Solution, NFL, University, Unitus Seed Fund, UCLA School of Dentistry, Stryker, Biomarker, LECOM Health Challenge, Forme, Partner, Risk, Intellectual property, Board, Marketing, NSE, NRGN, Medical imaging, Pharmaceutical industry, Medical device, Biology, Medicine

RICHMOND, Va., Oct. 4, 2022 /PRNewswire/ -- BRAINBox Solutions, Inc announced today that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and prognostic solutions the company is developing for mTBI.

Key Points: 
  • "BRAINBox's test is the first to integrate blood biomarkers with functional testing for both the diagnosis and prognosis of mild TBI," said Donna Edmonds, BRAINBox Solutions' Chief Executive Officer.
  • "The new BDNF patent is an important addition to our broad, worldwide portfolio of patents covering biomarkers related to various aspects of diagnostic use.
  • The newly allowed patent is based on BRAINBox Solutions' discovery that a decrease in blood levels of BDNF alone are sensitive and specific in the detection of mild TBI.
  • BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion.